<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090957</url>
  </required_header>
  <id_info>
    <org_study_id>MIT-Do001-C302</org_study_id>
    <nct_id>NCT04090957</nct_id>
  </id_info>
  <brief_title>Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women</brief_title>
  <acronym>E4Comfort</acronym>
  <official_title>A Randomized Double-blind Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Estetra</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Estetra</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or
      placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and
      the safety of E4 20 mg (Safety Study Part).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      &quot;This is a two-part study:

        -  The first part is the Efficacy Study mainly designed to evaluate the frequency and
           severity of vasomotor symptoms [VMS] in both hysterectomized and non hysterectomized
           postmenopausal participants after treatment with two doses of E4 (15 mg or 20 mg) or
           placebo for 12 consecutive weeks. Thereafter treatment will proceed for a total duration
           of 52 weeks, to continue the evaluation of secondary efficacy, safety and the effect on
           the endometrium. For endometrial protection, all non-hysterectomized subjects will
           receive treatment with 200 mg progesterone (P4) once daily for 14 consecutive days,
           after completion of the E4/placebo treatment.

        -  The second part is the Safety Study designed to evaluate the general safety, secondary
           efficacy (Lipid, glucose metabolism, health-related quality of life [HRQoL] and
           treatment satisfaction [TS]) after treatment with E4 20 mg for one year in
           hysterectomized postmenopausal participants.&quot;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are 3 blinded arms in the Efficacy part and 1 open-labeled arm in the Safety part.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>There are 3 blinded arms in the Efficacy part and 1 open-labeled arm in the Safety part.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in weekly frequency of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 4 (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 4 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 4.
Mean change = mean weekly frequency at Week 4 - mean weekly frequency at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in weekly frequency of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 12 (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 12 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 12.
Mean change = mean weekly frequency at Week 12 - mean weekly frequency at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in severity of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 4 (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 4 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 4.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 4 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 4 - mean severity score at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in severity of moderate to severe vasomotor symptoms (VMS) from Baseline to Week 12 (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 12 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 12.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 12 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 12 - mean severity score at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs) (Safety part)</measure>
    <time_frame>From Baseline to Week 53</time_frame>
    <description>Treatment emergent adverse events (TEAEs) are those adverse events occurring from time point of first ingestion of the study until last visit or any event already present that worsens in either intensity or frequency following exposure to the treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in physical and gynecological examination results (Safety part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>Physical examination will include an examination of general appearance, head, eyes, ears, nose, throat, skin neck, lungs, breast, lymph nodes, abdomen, and the cardiovascular musculoskeletal and neurological systems.
Gynecological examination will include a manual pelvic examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in vital sign results (Safety part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>Vital signs will include height, body weight, body mass index, sitting systolic and diastolic blood pressures, and heart rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in electrocardiogram (ECG) results (Safety part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>The ECG interpretation scheme will include the analysis of the morphology, rhythm, conduction, ST segment, PR, QRS, QT and corrected QT (QTc) intervals, T waves, U waves and the presence or absence of any pathological changes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in mammography results (Safety part)</measure>
    <time_frame>Screening and Week 53</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in breast examination results (Safety part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>Breast examination will include a manual breast examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with changes in routine clinical laboratory test (hematology and chemistry) results (Safety part)</measure>
    <time_frame>Screening, Baseline and Week 53</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 1 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 1</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 1 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 1.
Mean change = mean weekly frequency at Week 1 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 2 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 2 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 2.
Mean change = mean weekly frequency at Week 2 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 3 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 3</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 3 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 3.
Mean change = mean weekly frequency at Week 3 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 4 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 4 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 4.
Mean change = mean weekly frequency at Week 4 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 5 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 5</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 5 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 5.
Mean change = mean weekly frequency at Week 5 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 6 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 6 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 6.
Mean change = mean weekly frequency at Week 6 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 7 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 7</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 7 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 7.
Mean change = mean weekly frequency at Week 7 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 8 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 8 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 8.
Mean change = mean weekly frequency at Week 8 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 9 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 9</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 9 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 9.
Mean change = mean weekly frequency at Week 9 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 10 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 10</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 10 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 10.
Mean change = mean weekly frequency at Week 10 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 11 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 11</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 10 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 11.
Mean change = mean weekly frequency at Week 11 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 12 in the weekly frequency of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 12 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 12.
Mean change = mean weekly frequency at Week 12 - mean weekly frequency at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 1 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 1</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 1 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 1.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 1 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 1 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 2 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 2 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 2.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 2 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 2 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 3 the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 3</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 3 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 3.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 3 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 3 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 4 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 4 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 4.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 4 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 4 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 5 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 5</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 5 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 5.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 5 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 5 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 6 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 6 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 6.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 6 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 6 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 7 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 7</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 7 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 7.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 7 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 7 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 8 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 8 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 8.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 8 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 8 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 9 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 9</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 9 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 9.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 9 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 9 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 10 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 10</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 10 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 10.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 10 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 10 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 11 in the severity of moderate to severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 11</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 11 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 11.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 11 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 11 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 12 in the severity of mild, moderate to severe VMS (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The mean severity score of VMS at Baseline and Week 12 is defined as the arithmetic mean of the daily severity score values of moderate and severe VMS observed from the last 7 days prior randomization for Baseline and of mild, moderate and severe VMS observed at Week 12.
Baseline severity score = [(2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of moderate + severe VMS).
Week 12 severity score = [(1 x number of mild VMS) + (2 x number of moderate VMS) + (3 x number of severe VMS)]/ (total number of mild + moderate + severe VMS).
Mean change = mean severity score at Week 12 - mean severity score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 1 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 1</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 1 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 1.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 1 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 1 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 2 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 2 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 2.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 2 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 2 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 3 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 3</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 3 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 3.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 3 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 3 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 4 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 4 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 4.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 4 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 4 - mean weekly weighted score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 5 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 5</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 5 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 5.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 5 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 5 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 6 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 6 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 6.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 6 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 6 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to Week 7 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 7</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 7 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 7.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 7 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 7 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 8 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 8 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 8.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 8 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 8 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 9 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 9</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 9 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 9.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 9 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 9 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 10 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 10</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 10 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 10.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 10 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 10 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 11 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 11</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 11 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 11.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 11 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 11 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 12 in the weekly frequency and severity of moderate and severe vasomotor symptoms (VMS) (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This endpoint also called VMS weekly weighted score takes into account both the frequency and the severity of VMS.
The weekly frequency and severity of moderate and severe VMS at Baseline and at Week 12 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization for Baseline and at Week 12.
The severity score is derived as follows: mild = 1, moderate = 2, and severe = 3.
The weekly weighted score will be computed as follows:
Baseline weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Week 12 weekly weighted score = (2 x number of moderate VMS) + (3 x number of severe VMS)
Mean change = mean weekly weighted score at Week 12 - mean weekly weighted score at at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with 50% reduction from Baseline in the weekly frequency of moderate to severe vasomotor symptoms (VMS) at Week 4 (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 4 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization (Baseline) and days 22 to 28 (Week 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with 50% reduction from Baseline in the weekly frequency of moderate to severe VMS at Week 12 (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 12 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization (Baseline) and days 78 to 84 (Week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with 75% reduction from Baseline in the weekly frequency of moderate to severe VMS at Week 4 (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The weekly frequency of moderate to severe VMS at Baseline and Week 4 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization (Baseline) and days 22 to 28 (Week 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with 75% reduction from Baseline in the weekly frequency of moderate to severe VMS at Week 12 (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The weekly frequency of moderate to severe VMS at baseline and W eek 12 is defined as the total number (sum) of all recorded moderate to severe VMS experienced during the last 7 consecutive days prior randomization (baseline) and days 78 to 84 (week 12).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a clinically important difference (CID) compared to Baseline in the weekly frequency of moderate to severe VMS at Week 4 using the Clinical Global Impression (CGI) questionnaire (Efficacy part)</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The CGI score is a seven point scale in which subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses - Very Much Improved and Much Improved, and No Change or Worsening (Minimally worse, Much worse, Very much worse) - were combined for each Estetrol treatment groups compare to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with a clinically important difference (CID) compared to baseline in the weekly frequency of moderate to severe VMS at Week 12 using the Clinical Global Impression (CGI) questionnaire (Efficacy part)</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The CGI score is a seven point scale in which subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses - Very Much Improved and Much Improved, and No Change or Worsening (Minimally worse, Much worse, Very much worse) - were combined for each Estetrol treatment groups compare to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Prothrombin fragment 1+2 (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin potential (ETP)-based activated Protein C sensitivity ratio (APCsr ETP) (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated partial thromboplastin time (aPTT) based activated Protein C resistance (APCr) (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of anti-thrombin III (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Protein-C (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of free Protein-S (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of factor VIII (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of angiotensinogen (Efficacy part)</measure>
    <time_frame>Baseline, Week 13 and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration Sex Hormone Binding Globulin (SHBG) (Efficacy part)</measure>
    <time_frame>Baseline, Week 13 and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of triglycerides (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of high-density lipoprotein (HDL)-cholesterol (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of low-density lipoprotein (LDL)-cholesterol (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of lipoprotein(a) (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol/HDL-cholesterol ratio (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of total cholesterol (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of fasting glucose (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of insulin (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of glycated hemoglobin (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment-estimated insulin resistance (HOMA-IR) (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of procollagen I N-propeptide (PINP) (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of C-terminal telopeptide type 1 (CTX-1) (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of calcium (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of Vitamine D (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life assessment using the Menopause-specific Quality of Life (MENQOL) questionnaire (Efficacy part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
    <description>The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being &quot;not at all bothered&quot; and 8 being &quot;extremely bothered&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score in treatment satisfaction using the Clinical Global Impression (CGI)questionnaire (Efficacy part)</measure>
    <time_frame>Weeks 4, 12 and 52</time_frame>
    <description>The CGI score is a seven point scale in which subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses - Very Much Improved and Much Improved, and No Change or Worsening (Minimally worse, Much worse, Very much worse) - were combined for each estetrol treatment groups compare to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs) (Efficacy part)</measure>
    <time_frame>From baseline to Follow-up visit (up to Week 56)</time_frame>
    <description>Treatment emergent AEs (TEAEs) are those adverse events occurring from time point of first ingestion of the study until last visit or any event already present that worsens in either intensity or frequency following exposure to the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in physical and gynecological examination results (Efficacy part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>Physical examination will include an examination of general appearance, head, eyes, ears, nose, throat, skin neck, lungs, breast, lymph nodes, abdomen, and the cardiovascular musculoskeletal and neurological systems.
Gynecological examination will include a manual pelvic examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in vital sign results (Efficacy part)</measure>
    <time_frame>From screening to Week 53</time_frame>
    <description>Vital signs will include height, body weight, body mass index, sitting systolic and diastolic blood pressures, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in electrocardiogram (ECG) results (Efficacy part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>The ECG interpretation scheme will include the analysis of the morphology, rhythm, conduction, ST segment, PR, QRS, QT and QTc intervals, T waves, U waves and the presence or absence of any pathological changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in mammography results (Efficacy part)</measure>
    <time_frame>Screening and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with changes in breast examination results (Efficacy part)</measure>
    <time_frame>Screening and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with changes in routine clinical laboratory test results (Efficacy part)</measure>
    <time_frame>Screening, Baseline and Week 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean endometrial thickness (Efficacy part)</measure>
    <time_frame>Screening, Baseline, Weeks 13, 29, 53, and Follow-up (Week 55/56)</time_frame>
    <description>Endometrial thickness will be assessed by transvaginal ultrasound (TVUS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial biopsy histology at Screening and Week 53 (Efficacy part)</measure>
    <time_frame>Screening and Week 53</time_frame>
    <description>Endometrial biopsies will be centrally evaluated by 3 independent expert pathologists from different institutions. Two independent pathologists will assess the slides from the endometrial biopsies. In case of discrepancy between both pathologists' assessments, a third independent pathologist will assess the slide. If there is no agreement among the three pathologists, the most severe pathologic diagnosis will be used as the final diagnosis. Endometrial biopsy will be classified using criteria described in Blaustein's Pathology text into 1 of following 11 categories: Cat.0: No tissue; Cat.1: Tissue insufficient for diagnosis; Cat.2: Atrophic; Cat 3: Inactive; Cat 4: Proliferative; Cat 5: Secretory; Cat 6: Menstrual type; Cat 7: Simple hyperplasia without atypia; Cat 8: Simple hyperplasia with atypia; Cat 9: Complex hyperplasia without atypia; Cat 10: Complex hyperplasia with atypia; and Cat 11: Carcinoma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with vaginal bleeding and/or spotting during each 28-day cycle of treatment with E4 (Efficacy part)</measure>
    <time_frame>From Baseline up to Follow-up (Week 55/56)</time_frame>
    <description>Vaginal bleeding will be daily recorded by the participant on the diary. Absence or occurrence of vaginal bleeding/ spotting will be assessed using the scale below: 0 = Absence of vaginal bleeding or spotting; 1 = Spotting: evidence of minimal blood loss requiring none or at most one pad, tampon or panty liner per day; 2 = Bleeding: evidence of blood loss requiring more than one pad, tampon or panty liner per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of women with amenorrhea (absence of any bleeding or spotting) during each 28-day cycle of treatment with E4 (Efficacy part)</measure>
    <time_frame>From Baseline up to Follow-up (Week 55/56)</time_frame>
    <description>Vaginal bleeding will be daily recorded by the participant on the diary. Absence or occurrence of vaginal bleeding/ spotting will be assessed using the scale below: 0 = Absence of vaginal bleeding or spotting; 1 = Spotting: evidence of minimal blood loss requiring none or at most one pad, tampon or panty liner per day; 2 = Bleeding: evidence of blood loss requiring more than one pad, tampon or panty liner per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of triglycerides (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of HDL-cholesterol (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of LDL-cholesterol (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of total cholesterol (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of lipoprotein(a) (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of fasting glucose (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol/HDL-cholesterol ratio (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of glycated hemoglobin (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of insulin (Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Homeostasis model assessment-estimated insulin resistance (HOMA-IR)(Safety part)</measure>
    <time_frame>Baseline, Weeks 13 and 53</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life assessment using the Menopause-specific Quality of Life (MENQOL) questionnaire (Safety part)</measure>
    <time_frame>Baseline, Weeks 12 and 52</time_frame>
    <description>The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being &quot;not at all bothered&quot; and 8 being &quot;extremely bothered&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score in treatment satisfaction using the Clinical Global Impression (CGI) questionnaire (Safety part)</measure>
    <time_frame>Weeks 4, 12 and 52</time_frame>
    <description>The CGI score is a seven point scale in which subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses - Very Much Improved and Much Improved, and No Change or Worsening (Minimally worse, Much worse, Very much worse) - were combined for each estetrol treatment groups compare to placebo.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Vasomotor Symptoms</condition>
  <condition>Menopausal Symptoms</condition>
  <arm_group>
    <arm_group_label>Estetrol 15 mg - Efficacy Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estetrol (E4) 15 mg will be administered orally once daily for 52 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estetrol 20 mg - Efficacy Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Efficacy Part</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered orally once daily for 52 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estetrol 20 mg - Safety Part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estetrol oral tablet</intervention_name>
    <description>Estetrol oral tablet will be administered orally once daily.</description>
    <arm_group_label>Estetrol 15 mg - Efficacy Part</arm_group_label>
    <arm_group_label>Estetrol 20 mg - Efficacy Part</arm_group_label>
    <arm_group_label>Estetrol 20 mg - Safety Part</arm_group_label>
    <other_name>E4 oral tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo oral tablet will be administered orally once daily.</description>
    <arm_group_label>Placebo - Efficacy Part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated written informed consent form and any required privacy authorization
             prior to the initiation of any trial procedure, after the nature of the trial has been
             explained according to local regulatory requirements;

          2. Females  40 up to  65 years of age at randomization;

          3. For hysterectomized subjects: documented hysterectomy must have occurred at least 6
             weeks prior to the start of screening. Hysterectomy can be total or subtotal (i.e.,
             cervix was not removed).

          4. For non-hysterectomized subjects: endometrial biopsy taken during screening that
             reveals no abnormal results, i.e., presence of hyperplasia (simple or complex, with or
             without atypia), presence of carcinoma, and presence of disordered proliferative
             findings. The screening biopsy should have sufficient endometrial tissue for
             diagnosis. Biopsies without tissue or with insufficient tissue may be repeated once;

          5. Seeking treatment for relief of VMS associated with menopause;

               1. For the Efficacy Study part: at least 7 moderate to severe bothersome VMS per day
                  or at least 50 moderate to severe bothersome VMS per week in the last 7
                  consecutive days during the Screening period;

               2. For the Safety Study part: at least 1 moderate to severe VMS per week;

          6. Body mass index  18.0 kg/m to  38.0 kg/m;

          7. A mammogram that shows no sign of significant disease performed during screening or
             within 9 months prior to the start of screening;

          8. Post-menopausal status defined as any of the following:

               1. For non-hysterectomized subjects:

                    -  At least 12 months of spontaneous amenorrhea with serum follicle stimulating
                       hormone (FSH) &gt;40 milli-International unit (mIU)/mL (value obtained after
                       washout of estrogen/progestin containing drugs, see exclusion criteria 18
                       and 20);

                    -  or at least 6 months of spontaneous amenorrhea with serum FSH &gt;40 mIU /mL
                       and E2 &lt;20 pg/mL (value obtained after washout of estrogen/progestin
                       containing drugs, see exclusion criteria 18 and 20);

                    -  or at least 6 weeks postsurgical bilateral oophorectomy;

               2. For hysterectomized subjects:

                    -  serum FSH &gt;40 mIU/mL and E2 &lt;20 pg/mL (values obtained after washout of
                       estrogen/progestin containing drug see exclusion criteria 18 and 20);

                    -  or at least 6 weeks post-surgical bilateral oophorectomy;

          9. Good physical and mental health, in the judgement of the Investigator as based on
             medical history, physical and gynecological examination, and clinical assessments
             performed prior to Visit 1;

         10. Able to understand and comply with the protocol requirements, instructions, and
             protocol-stated restrictions;

         11. Able and willing to complete trial daily diaries and questionnaires.

        Exclusion Criteria:

          1. History of malignancy with the exception of basal cell or squamous cell carcinoma of
             the skin if diagnosed more than 1 year prior to the Screening visit;

          2. Any clinically significant findings found by the Investigator at the breast
             examination and/or on mammography suspicious of breast malignancy that would require
             additional clinical testing to rule out breast cancer (however, simple cysts confirmed
             by ultrasound are allowed);

          3. Papanicolaou (PAP) test with atypical squamous cells undetermined significance
             (ASC-US) or higher (low-grade intraepithelial lesion [LSIL], atypical squamous cells-
             cannot exclude high-grade squamous intraepithelial lesion [HSIL] [ASC-H], HSIL
             dysplastic or malignant cells) in sub-totally hysterectomized and non-hysterectomized
             subjects. Note: ASC-US is allowed if a reflex human papilloma virus (HPV) testing is
             performed and is negative for high risk oncogene HPV;

          4. For non-hysterectomized subjects:

               1. History or presence of uterine cancer, endometrial hyperplasia, disordered
                  proliferative findings;

               2. Presence of endometrial polyp;

               3. Undiagnosed vaginal bleeding;

               4. Endometrial ablation;

               5. Enlarged uterus with myoma;

          5. Systolic blood pressure (BP) higher than 130 mmHg, diastolic BP higher than 80 mmHg
             during screening;

          6. History of venous or arterial thromboembolic disease (e.g., superficial or deep vein
             thrombosis, pulmonary embolism, stroke, myocardial infarction, angina pectoris, etc.),
             or first degree family history of venous thromboembolism (VTE);

          7. History of known acquired of congenital coagulopathy or abnormal coagulation factors,
             including known thrombophilia's;

          8. Diabetes mellitus with poor glycemic control in the last 6 months assessed by
             laboratory values of fasting glucose outside the normal ranges and glycated hemoglobin
             above 7%;

          9. Dyslipoproteinaemia (LDL &gt;190 mg/dL and triglycerides &gt;300 mg/dL);

         10. Smoking:

               1. Efficacy Study part: subjects smoking &gt;5 cigarettes per day or &gt;2 packs per week;

               2. Safety Study part: subjects smoking &gt;15 cigarettes per day or &gt;6 packs per week;

         11. Presence or history of gallbladder disease, unless cholecystectomy has been performed;

         12. Systemic lupus erythematosus;

         13. Any malabsorption disorders including gastric by-pass surgery;

         14. History of acute liver disease in the preceding 12 months before the start of
             screening or presence of chronic liver disease [alanine transaminase (ALT) or
             aspartate transaminase (AST) &gt;2 x upper limit of normal (ULN), bilirubin &gt;1.5 ULN];

         15. Chronic or current acute renal impairment (estimated glomerular filtration rate &lt;60
             ml/min);

         16. Porphyria;

         17. Diagnosis or treatment of major psychiatric disorder (e.g., schizophrenia, bipolar
             disorder, etc.) in the judgement of the Investigator

         18. Use of estrogen/progestin containing drug(s) up to:

               1. 1 week before screening start for vaginal non systemic hormonal products (rings,
                  creams, gels);

               2. 4 weeks before screening start for vaginal or transdermal estrogen or
                  estrogen/progestin products;

               3. 8 weeks before screening start for oral estrogen and/or progestin products and/or
                  selective estrogen receptor modulator therapy;

               4. 8 weeks before screening start for intrauterine progestin therapy;

               5. 3 months before screening start for progestin implants or estrogen alone
                  injectable drug therapy;

               6. 6 months before screening start for estrogen pellet therapy or progestin
                  injectable drug therapy;

         19. Use of androgen/dehydroepiandrosterone (DHEA) containing drugs:

               1. 8 weeks before screening start for oral, topical, vaginal or transdermal
                  androgen;

               2. 6 months before screening start for implantable or injectable androgen therapy;

         20. Use of phytoestrogens or black cohosh for treatment of VMS up to 2 weeks before the
             start of screening;

         21. For the women participating in the Efficacy Study part: use of prescription or
             over-the-counter products used for the treatment of VMS, e.g., anti-depressants:
             paroxetine, escitalopram, methyldopa, opioid and clonidine up to 4 weeks before the
             start of screening, and venlafaxine and desvenlafaxine up to 3 months before the start
             of screening , and not willing to stop these during their participation in the trial;

         22. Not willing to stop any hormonal products as described in exclusion criteria 18, 19
             and 20 during their participation in the trial;

         23. Inadequately treated hyperthyroidism at screening;

         24. History or presence of allergy/intolerance to the investigational product or drugs of
             this class or any component of it, or history of drug or other allergy that, in the
             opinion of the Investigator contraindicates subject participation;

         25. For non-hysterectomized subjects: history or presence of allergy to peanuts;

         26. History of alcohol or substance abuse (including marijuana, even if legally allowed)
             or dependence in the previous 12 months before the start of screening as determined by
             the Investigator, based on reported observations;

         27. Sponsor or contract research organization (CRO) employees or employees under the
             direct supervision of the Investigator and/or involved directly in the trial;

         28. Subjects with known or suspected history of a clinically significant systemic disease,
             unstable medical disorders, life-threatening disease or current malignancies that
             would pose a risk to the subject in the opinion of the Investigator;

         29. Participation in another investigational drug clinical trial within 1 month (30 days)
             or having received an investigational drug within the last 1 month (30 days) before
             the start of screening;

         30. Is judged by the Investigator to be unsuitable for any reason.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Estetra</last_name>
    <role>Study Director</role>
    <affiliation>Estetra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Estetra</last_name>
    <phone>003243492822</phone>
    <email>clinical.trials@mithra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldbaum Arthur, M.D.</last_name>
      <email>mailto:drwaldbaum@md4women.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estetrol</keyword>
  <keyword>Hot Flushes</keyword>
  <keyword>Vasomotor symptoms</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

